Clinical research by Zepbound's manufacturer Eli Lilley found that the drug's active ingredient tirzepatide reduces sleep apnea by about 60%.

During FDA-declared shortages, pharmacists can legally make compounded versions of brand-name medications. But drugmakers and ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

GLP-1 receptor agonist weight loss drugs can negatively interact with eating disorder psychopathology and treatment in ...

The FDA on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug ...

Tirzepatide was favored over ... are associated with reduced apnea-hypopnea index (AHI), body mass index (BMI), weight, and ...

Elon Musk has admitted to taking a weight-loss drug in a Christmas Day post on X, formerly Twitter, as he shared a picture of ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...